Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429869 · ClinicalTrials.gov registry record · Phase 4
Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02429869 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants.
The verdict
NCT02429869, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition may favorably impact the HIV viral reservoir, and we hypothesize that adding everolimus to the transplant immunosuppressive regimen of HIV positive transplant recipients will decrease HIV persistence in CD4+ lymphocytes.
Interventions
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02429869
The ClinicalTrials.gov registry entry for NCT02429869 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which everolimus is the first listed.
NCT02429869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02429869 about?
NCT02429869 is a clinical study titled "Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant". Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition may favorably impact the HIV viral reservoir, and we hypothesize that adding everolimus to the transplant immunosuppressi...
What is the current status of trial NCT02429869?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2016-02-24. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02429869?
The interventions under investigation include: everolimus (DRUG).
Who is sponsoring clinical trial NCT02429869?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.